CD44介导的代谢重新连接是IDH突变白血病的可向依赖性
Junhua Lyu1, Yuxuan Liu2, Ningning Liu2
1Center of Excellence for Leukemia Studies, Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Blood
|January 22, 2025
概括
向白血病中的异酸脱酶 (IDH) 突变是有希望的,但耐药性很常见. 新的研究表明,CD44激活驱动IDH突变白血病代谢,这表明IDH和CD44结合阻断是有效的治疗方法.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 复发的异酸脱酶 (IDH) 突变通过代代谢物 (R) - 2 - 基酸盐 (R-2HG) 的产生促进瘤发生.
- 在急性髓性白血病 (AML) 中,IDH 抑制显得有前途,但面临阻力,需要新的治疗策略.
研究的目的:
- 在IDH突变白血病中确定新的治疗点.
- 为了阐明CD44在IDH突变白血病代谢和生存中的作用.
主要方法:
- 对具有CRISPR基编辑IDH突变的同源白血病细胞进行比较转录组分析.
- 研究CD44在代谢途径中的作用,包括酸途径和糖解.
- 使用IDH抑制和CD44阻塞的组合疗法的评估.
主要成果:
- CD44激活是IDH突变白血病的共同特征,与IDH突变AML患者的高表达相关.
- CD44通过激活酸路径和抑制糖解,促进NADPH生成以产生R-2HG.
- 联合的IDH抑制和CD44阻断显著增强了IDH突变白血病细胞的消除.
结论:
- CD44通过代谢重新连接驱动一种瘤原性前途径,以支持IDH突变白血病中R-2HG的产生.
- CD44代表了IDH突变恶性瘤中潜在的可向依赖性.
- 针对IDH和CD44的组合疗法为克服IDH突变AML的耐药性提供了一个有希望的策略.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Electron Transport Chain: Complex I and II
10.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.7K


